| Date | Time | Room | Session Title | Presentation Time | Topic | Role |
|---|---|---|---|---|---|---|
| 23/03/2024 | 10:20 to 10:45 | Plenary (Di Cavalcanti) |
Plenary Simpósio Ginecologia Lecture - Module 3: Pathology, Genetics, Ovarian Masses, Early Ovarian Cancer |
10:20 to 10:30 | Postoperative systemic treatment of early ovarian cancer: routine favor Postoperative systemic treatment of early ovarian cancer: routine favor | Speaker |
| 23/03/2024 | 10:20 to 10:45 | Plenary (Di Cavalcanti) |
Plenary Simpósio Ginecologia Lecture - Module 3: Pathology, Genetics, Ovarian Masses, Early Ovarian Cancer |
10:40 to 10:45 | Discussion | Discussant |
| 23/03/2024 | 13:35 to 14:55 | Plenary (Di Cavalcanti) |
Plenary Simpósio Ginecologia Lecture - Module 4: Advanced Ovarian Cancer |
13:35 to 13:50 | Incorporation of bevacizumab into the first-line treatment of advanced ovarian cancer: results and indications | Speaker |
| 23/03/2024 | 13:35 to 14:55 | Plenary (Di Cavalcanti) |
Plenary Simpósio Ginecologia Lecture - Module 4: Advanced Ovarian Cancer |
13:50 to 13:55 | Discussion | Discussant |
| 23/03/2024 | 13:35 to 14:55 | Plenary (Di Cavalcanti) |
Plenary Simpósio Ginecologia Lecture - Module 4: Advanced Ovarian Cancer |
14:15 to 14:30 | Maintenance PARP inhibitors in ovarian cancer after first-line treatment: results and who are the ideal patients? | Speaker |
| 23/03/2024 | 13:35 to 14:55 | Plenary (Di Cavalcanti) |
Plenary Simpósio Ginecologia Lecture - Module 4: Advanced Ovarian Cancer |
14:30 to 14:35 | Discussion | Discussant |